pioglitazone has been researched along with Cirrhoses, Experimental Liver in 5 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pioglitazone treatment decreases portosystemic shunting via modulation of splanchnic inflammation and neoangiogenesis." | 7.80 | Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. ( Angermayr, B; Boucher, Y; Fuhrmann, V; Grahovac, J; Horvatits, T; Klein, S; Mitterhauser, M; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Schwabl, P; Stift, J; Trauner, M; Trebicka, J, 2014) |
| "Non-alcoholic steatohepatitis (NASH) may progress to liver cirrhosis, and NASH patients with liver cirrhosis have a risk of development of hepatocellular carcinoma." | 5.32 | Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. ( Kawaguchi, K; Okita, K; Omori, K; Sakaida, I; Takami, T; Tsuchiya, M, 2004) |
| "Pioglitazone treatment decreases portosystemic shunting via modulation of splanchnic inflammation and neoangiogenesis." | 3.80 | Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. ( Angermayr, B; Boucher, Y; Fuhrmann, V; Grahovac, J; Horvatits, T; Klein, S; Mitterhauser, M; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Schwabl, P; Stift, J; Trauner, M; Trebicka, J, 2014) |
| "Treatment with pioglitazone caused an increase in body weight gain in Pemt(-/-) mice that was mainly due to increased adiposity." | 1.43 | Pioglitazone attenuates hepatic inflammation and fibrosis in phosphatidylethanolamine N-methyltransferase-deficient mice. ( Armstrong, EA; Gao, X; Jacobs, RL; Kassiri, Z; Lehner, R; Lingrell, S; Quiroga, AD; Takawale, A; van der Veen, JN; Vance, DE; Yager, JY, 2016) |
| "Pioglitazone treatment was introduced at various time points." | 1.33 | Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats. ( Horsmans, Y; Leclercq, IA; Sempoux, C; Stärkel, P, 2006) |
| "Non-alcoholic steatohepatitis (NASH) may progress to liver cirrhosis, and NASH patients with liver cirrhosis have a risk of development of hepatocellular carcinoma." | 1.32 | Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. ( Kawaguchi, K; Okita, K; Omori, K; Sakaida, I; Takami, T; Tsuchiya, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schwabl, P | 1 |
| Payer, BA | 1 |
| Grahovac, J | 1 |
| Klein, S | 1 |
| Horvatits, T | 1 |
| Mitterhauser, M | 1 |
| Stift, J | 1 |
| Boucher, Y | 1 |
| Trebicka, J | 1 |
| Trauner, M | 1 |
| Angermayr, B | 1 |
| Fuhrmann, V | 1 |
| Reiberger, T | 1 |
| Peck-Radosavljevic, M | 1 |
| Aghaei, I | 1 |
| Shabani, M | 1 |
| Doustar, N | 1 |
| Nazeri, M | 1 |
| Dehpour, A | 1 |
| van der Veen, JN | 1 |
| Lingrell, S | 1 |
| Gao, X | 1 |
| Quiroga, AD | 1 |
| Takawale, A | 1 |
| Armstrong, EA | 1 |
| Yager, JY | 1 |
| Kassiri, Z | 1 |
| Lehner, R | 1 |
| Vance, DE | 1 |
| Jacobs, RL | 1 |
| Kawaguchi, K | 1 |
| Sakaida, I | 1 |
| Tsuchiya, M | 1 |
| Omori, K | 1 |
| Takami, T | 1 |
| Okita, K | 1 |
| Leclercq, IA | 1 |
| Sempoux, C | 1 |
| Stärkel, P | 1 |
| Horsmans, Y | 1 |
5 other studies available for pioglitazone and Cirrhoses, Experimental Liver
| Article | Year |
|---|---|
Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats.
Topics: Animals; Cell Movement; Disease Models, Animal; Hemodynamics; Human Umbilical Vein Endothelial Cells | 2014 |
Peroxisome proliferator-activated receptor-γ activation attenuates motor and cognition impairments induced by bile duct ligation in a rat model of hepatic cirrhosis.
Topics: Animals; Avoidance Learning; Bile Duct Diseases; Bile Ducts; Cognition Disorders; Hypoglycemic Agent | 2014 |
Pioglitazone attenuates hepatic inflammation and fibrosis in phosphatidylethanolamine N-methyltransferase-deficient mice.
Topics: Actins; Adipocytes, White; Adipose Tissue, White; Adiposity; Animals; Anti-Infective Agents; Cell Pr | 2016 |
Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet.
Topics: Amino Acids; Animal Feed; Animals; Biomarkers; Body Weight; Choline Deficiency; Fatty Liver; Fibrosi | 2004 |
Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats.
Topics: Animals; Bile Ducts; Carbon Tetrachloride; Choline; Collagen Type I; Disease Progression; Hypoglycem | 2006 |